E Therapeutics (ETX)

 

ETX Share PerformanceMore

52 week high27.5000 17/12/15
52 week low8.3000 24/11/16
52 week change -17.1250 (-67.16%)
4 week volume720,053 09/11/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Grant of share options and Directors' dealings

RNS Number: 9836P e-Therapeutics plc 23 November 2016 23 November 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Grant of share options and Directors' dealings Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total o...

Director Deals - e-Therapeutics PLC (ETX)

Prof Trevor Jones, Non Executive Director, bought 41,204 shares in the company on the 5th October 2016 at a price of 11.33p...

Directors' Dealings and Issue of Equity

RNS Number: 8817L e-Therapeutics plc 06 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Directors' Dealings and Issue of Equity Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that o n 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,20...

Further re: Directors' Shareholdings

RNS Number: 5273L e-Therapeutics plc 03 October 2016 e-Therapeutics plc ('e-Therapeutics' or 'the Company') Further re: Directors' Shareholdings 3 October 2016, Oxford and Newcastle, UK: Further to e-Therapeutics' announcement on 21 September 2016, the Company announces the following additional detail on the increase to Sean Nicolson's shareholding in the Com...

Issue of Equity and Directors' shareholdings

Notification of an issue of equity shares e.g. offer for subscription/offer for sale/rights issue

e-Therapeutics operating losses rise

e-Therapeutics posts an operating loss of 9.7m for the six months to the end of July (HY15: loss of 5.9m), including 2.1m good...

Half year results

Announcement of half-year/second quarter financial results

Management Update

Miscellaneous medium priority announcements

Fundamental DataMore

EPS-3.34
Dividend yield0 %

Equity Research (ETX)

edison investment research
e-Therapeutics plc.
20/09/2016
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....
edison investment research
e-Therapeutics plc.
19/05/2016
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and...
edison investment research
e-Therapeutics plc.
18/02/2016
e-Therapeutics’ (ETX) share price fell c 30% on news that the ETS6103 Phase IIb trial as a second-line therapy for major depressive disorder (MDD) failed to meet its primary efficacy endpoint....

Latest discussion posts More

  • Results

    RNS available at company's website. although seems to be missing in III ...
    22-Mar-2016
    nk1999
  • Re: Good news but why?

    RNS out today afternoon. Good operational progress. Not sure if that warrants a steep rise in SP as seen over the last few days, including a further 15% today. But I ...
    26-Feb-2015
    nk1999
  • Re: Good news but why?

    Clearly somebody knows something we don't. Would that be called insider trading I wonder.
    26-Feb-2015
    Actinidia

Users' HoldingsMore

Users who hold E Therapeutics also hold..
RENEURON28%
LLOYDS GRP.28%
ROCKHOPPER21%
ID:ISIN:VGG9828A119417%
VALIRX17%

Codes & Symbols

ISINGB00B2823H99
SymbolsETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX